Selim Kul

Dr. Selim Kul


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2015 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
TTTurhan Turan
Turhan Turan
UMUmit Mentese
Umit Mentese
MAMustafa Tarik Agac
Mustafa Tarik Agac
AAAli Rıza Akyüz
Ali Rıza Akyüz
SKSelim Kul
Selim Kul
SCSukru Celik
Sukru Celik
Anadolu Kardiyoloji Dergisi, Anadolu Kardiyol Derg, The Anatolian Journal of Cardiology, Anatol J Cardiol, Cardiology, Cardiovascular Medicine, Surgery, Pediatric Cardiology, Angiology

29 September 2016 in Angiology
Verified
Journal Article
Closed access
TTTurhan Turan
Turhan Turan
MAMustafa Tarik Agac
Mustafa Tarik Agac
AAAhmet Çağrı Aykan
Ahmet Çağrı Aykan
SKSelim Kul
Selim Kul
AAAli Rıza Akyüz
Ali Rıza Akyüz
SCSukru Celik
Sukru Celik
In the present study, we aimed to evaluate temporal changes in heart-type fatty acid-binding protein (h-FABP) and myocardial performance index (Tei index) following administration of 5-fluorouracil (5-FU), a chemotherapeutic agent associated with myocardial ischemia induced by coronary vasospasm. Thirty-two patients with cancer receiving their first 5-FU-based chemotherapy were included in the study. Prior to chemotherapy and 24 hours after the initiation of chemotherapy, all patients underwent a comprehensive echocardiographic examination. Blood samples were taken for h-FABP and troponin I (TnI) measurements at different time points during the first 24 hours of 5-FU administration. Postinfusion echocardiography revealed worsening in Tei index (0.37 ± 0.08 vs 0.43 ± 0.07, P < .001). Clinically overt cardiotoxicity was evident in 4 (12.5%) of our patient population. Heart-type fatty acid binding protein and TnI levels were within normal ranges at all time points. Our results suggest that ischemia coronary vasospasm due to 5-FU cardiotoxicity should be reviewed. Furthermore, Tei index might be a sensitive indicator of occult 5-FU cardiotoxicity.

11 July 2016 in Angiology
Verified
Journal Article
Closed access
TTTurhan Turan
Turhan Turan
AAAli Rıza Akyüz
Ali Rıza Akyüz
AAAhmet Cagri Aykan
Ahmet Cagri Aykan
SKSelim Kul
Selim Kul
OCOmer Faruk Cirakoglu
Omer Faruk Cirakoglu
SCSukru Celik
Sukru Celik
Endocan is a soluble proteoglycan, secreted by human vascular endothelial cells. Endocan is a marker for vascular pathologies and an important mediator of angiogenesis, strongly associated with inflammation, vascular endothelial dysfunction, and atherosclerosis. The relationship between coronary artery ectasia (CAE) and endocan has not been evaluated. We aimed to investigate this association. Fifty-four patients with isolated CAE without coronary stenosis and 30 controls with normal coronary angiogram were included in this study. Endocan plasma concentrations were measured using an enzyme-linked immunosorbent assay. Patients with isolated CAE had significantly higher levels of endocan compared to the controls (18.9 ± 7.3 vs 15.6 ± 3.6 ng/mL; P = .007). There was a significant correlation between endocan levels and severity of isolated CAE according to the Markis classification (r = −.593, P < .001). Plasma endocan levels may reflect the presence and severity of isolated CAE, suggesting that endocan may be involved in pathogenesis of isolated CAE.

1 March 2019
Verified
Journal Article
Closed access
SKSelim Kul
Selim Kul
AKAysegul Karadeniz
Aysegul Karadeniz
IDIhsan Dursun
Ihsan Dursun
SSSinan Sahin
Sinan Sahin
OCOmer Faruk Cirakoglu
Omer Faruk Cirakoglu
AAAhmet Hakan Ates
Ahmet Hakan Ates

18 September 2013 in Angiology
Verified
Journal Article
Closed access
LKLevent Korkmaz
Levent Korkmaz
OCOmer Faruk Cirakoglu
Omer Faruk Cirakoglu
MAMustafa Tarık Ağaç
Mustafa Tarık Ağaç
HEHakan Erkan
Hakan Erkan
AKAyca Ata Korkmaz
Ayca Ata Korkmaz
ŞÇŞükrü Çelik
Şükrü Çelik
The main aim of the present study was to investigate the association between epicardial adipose tissue (EAT) and arterial function in patients with asymptomatic hypertension. Patients with hypertension (n = 155) were enrolled consecutively. Patients with decreased arterial compliance (AC) and increased cardioankle vascular index (CAVI) had higher EAT values compared with those with normal AC and CAVI (6.23 ± 1.67 vs 4.91 ± 1.40, P < .001 and 6.02 ± 1.61 vs 4.96 ± 1.46, P = .01, respectively). Analysis using the receiver–operating characteristics curve demonstrated that EAT 5.5 mm constitutes the cutoff value for the presence of increased CAVI with 67% sensitivity and 62% specificity (area under the curve [AUC]: 0.702, 95% confidence interval [CI] 0.590-0.814) and decreased AC with 77% sensitivity and 65% specificity (AUC: 0.756, 95% CI 0.645-0.867). Assessment of EAT during echocardiography examination may provide information on arterial function in patients with asymptomatic hypertension. The link between EAT and arterial stiffness deserves further investigation.

4 March 2024 in Archives of Medical Science
Verified
Journal Article
Open access
TKTeoman Kilic
Teoman Kilic
AIAlfonso Ielasi
Alfonso Ielasi
VNVlasis Ninios
Vlasis Ninios
LKLevent Korkmaz
Levent Korkmaz
DPDemosthenes Panagiotakos
Demosthenes Panagiotakos
AAAli Rıza Akyüz
Ali Rıza Akyüz
Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria.Material and methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria.Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%.Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.